The estimated Net Worth of Eric M Dube is at least $10 million dollars as of 18 September 2020. Eric Dube owns over 10,805 units of Retrophin stock worth over $6,629 and over the last 6 years he sold RTRX stock worth over $317,370. In addition, he makes $9,679,320 as President, Chief Executive Officer et Director at Retrophin.
Sign up
Eric Dube RTRX stock SEC Form 4 insiders trading
Eric has made over 2 trades of the Retrophin stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 10,805 units of RTRX stock worth $208,320 on 18 September 2020.
The largest trade he's ever made was selling 10,805 units of Retrophin stock on 18 September 2020 worth over $208,320. On average, Eric trades about 3,661 units every 51 days since 2019. As of 18 September 2020 he still owns at least 94,695 units of Retrophin stock.
You can see the complete history of Eric Dube stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Eric Dube biography
Dr. Eric Dube is President, Chief Executive Officer, Director of the Company. Prior to his employment with the Company, Dr. Dube served as the Head, North America of Viiv Healthcare Limited, a pharmaceuticals company, since January 2018. From June 2015 to December 2017, Dr. Dube served as Sr. Vice President and Head, Global Respiratory Franchise of GlaxoSmithKline Pharmaceuticals plc (“GSK”), a pharmaceutical company. From February 2013 to May 2015, Dr. Dube served as Senior Vice President and Business Unit Head, Respiratory Japan of GSK. Prior to that, Dr. Dube held senior leadership roles at GSK in Strategy, Planning & Operations, Oncology, Managed Markets and Marketing, and earlier in his career held other positions of increasing responsibility at GSK. Dr. Dube holds a B.S. from Santa Clara University and a M.A. and Ph.D. from Cornell University.
What is the salary of Eric Dube?
As the President, Chief Executive Officer et Director of Retrophin, the total compensation of Eric Dube at Retrophin is $9,679,320. There are no executives at Retrophin getting paid more.
How old is Eric Dube?
Eric Dube is 47, he's been the President, Chief Executive Officer et Director of Retrophin since 2019. There are 14 older and no younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.
What's Eric Dube's mailing address?
Eric's mailing address filed with the SEC is 3721 VALLEY CENTRE DR, #200, , SAN DIEGO, CA, 92130.
Insiders trading at Retrophin
Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer et Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.
What does Retrophin do?
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
What does Retrophin's logo look like?
Complete history of Eric Dube stock trades at Retrophin
Retrophin executives and stock owners
Retrophin executives and other stock owners filed with the SEC include:
-
Eric Dube,
President, Chief Executive Officer, Director -
Elizabeth Reed,
Senior Vice President, General Counsel and Corporate Secretary -
Noah Rosenberg,
Chief Medical Officer -
Peter Heerma,
Chief Commercial Officer -
William Rote,
Senior Vice President and Head of Research and Development -
Laura Clague,
Chief Financial Officer, Senior Vice President -
Stephen Aselage,
Director -
Sandra Poole,
Independent Director -
Gary Lyons,
Independent Chairman of the Board -
Timothy Coughlin,
Independent Director -
Jeffrey Meckler,
Independent Director -
John Orwin,
Independent Director -
Roy Baynes,
Independent Director -
Ron Squarer,
Independent Director -
Suzanne Bruhn,
Independent Director -
Neil F. Mc Farlane,
Chief Operating Officer -
Jensen Margaret E Valeur,
General Counsel -
John W Kozarich,
Director -
Alvin Shih,
EVP of Research & Development -
Cornelius E Golding,
Director -
Steve Aselage,
Director -
Martin Shkreli,
Chief Executive Officer -
Steven Gary Richardson,
Director -
Horacio Plotkin,
Chief Medical Officer -
Jeffrey Paley,
Director -
Marc L Panoff,
Chief Financial Officer